Cupping Therapy for the Treatment of Migraine Headache: a systematic review and meta-analysis of clinical trials.
cupping
headache
hijamah
meta-analysis
migraine
systematic review
Journal
Journal of pharmacopuncture
ISSN: 2093-6966
Titre abrégé: J Pharmacopuncture
Pays: Korea (South)
ID NLM: 101572812
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
13
05
2024
revised:
28
05
2024
accepted:
20
08
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
ppublish
Résumé
Cupping therapy is a widely used complementary medicine for the treatment of migraine headaches globally. However, conflicting evidence exists on its effectiveness. To evaluate the safety and efficacy of cupping therapy in treating migraine headache disorder. Seven databases were systematically searched PubMed/MEDLINE, Clinicaltrials.gov, Cochrane CENTRAL, ScienceDirect, ProQuest, SinoMed, and the National Science and Technology Library. The primary endpoints are the treatment success and the pain intensity reduction. The secondary endpoints were adverse events (AEs) risk and improvement in quality of life (QoL), which was based on the Migraine Disability Scale (MIDAS). Subgroup analyses were performed based on the cupping techniques (wet and dry cupping) and adjunctive complementary treatments (i.e. acupuncture and/or collateral pricking). Eighteen trials out of 348 records were included, pooling 1,446 participants (n = 797 received cupping therapy). Treatment success was significantly higher among those with cupping therapy (risk ratio [RR] [95% CI] = 1.83 [1.52-2.21]); with significant improvement observed only with wet cupping (RR [95% CI] = 1.88 [1.53-2.30]). The adjunctive complementary therapy did not achieve a greater amplitude of treatment success compared to cupping therapy alone. Furthermore, cupping therapy showed significant pain reduction compared to baseline (standardized mean difference [SMD] [95% CI] = 0.55 [0.39-0.70]) and achieved fewer risks of AEs (RR [95% CI] = 1.88 [1.53-2.30]). However, cupping did not improve the overall QoL (MIDAS SMD [95% CI] = -0.79 [-3.55-1.98]). Cupping therapy was an effective complementary modality to treat migraine headaches. However, it did not demonstrate improvement in QoL (PROSPERO CRD42024514509).
Identifiants
pubmed: 39350928
doi: 10.3831/KPI.2024.27.3.177
pii: jop-27-3-177
pmc: PMC11439517
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
177-189Informations de copyright
© 2024 Korean Pharmacopuncture Institute.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest in this work.